CN100482211C - 药物靶向的局部脂解 - Google Patents

药物靶向的局部脂解 Download PDF

Info

Publication number
CN100482211C
CN100482211C CNB2004800314111A CN200480031411A CN100482211C CN 100482211 C CN100482211 C CN 100482211C CN B2004800314111 A CNB2004800314111 A CN B2004800314111A CN 200480031411 A CN200480031411 A CN 200480031411A CN 100482211 C CN100482211 C CN 100482211C
Authority
CN
China
Prior art keywords
phospholipid
acid
purposes
weight
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800314111A
Other languages
English (en)
Chinese (zh)
Other versions
CN1870977A (zh
Inventor
P·博德克
R·波特
J·桑多
M·戈塞尔
K-H·尼奇
G·萨特勒
G·沃格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Sanofi Aventis Deutschland GmbH
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100482211(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH, Merz Pharma GmbH and Co KGaA filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1870977A publication Critical patent/CN1870977A/zh
Application granted granted Critical
Publication of CN100482211C publication Critical patent/CN100482211C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2004800314111A 2003-10-24 2004-10-09 药物靶向的局部脂解 Expired - Fee Related CN100482211C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349979.2 2003-10-24
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse

Publications (2)

Publication Number Publication Date
CN1870977A CN1870977A (zh) 2006-11-29
CN100482211C true CN100482211C (zh) 2009-04-29

Family

ID=34529797

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800314111A Expired - Fee Related CN100482211C (zh) 2003-10-24 2004-10-09 药物靶向的局部脂解

Country Status (13)

Country Link
EP (1) EP1684722B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509085A (cg-RX-API-DMAC7.html)
KR (1) KR20060117914A (cg-RX-API-DMAC7.html)
CN (1) CN100482211C (cg-RX-API-DMAC7.html)
AT (1) ATE418965T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285264A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415756A (cg-RX-API-DMAC7.html)
CA (1) CA2543187A1 (cg-RX-API-DMAC7.html)
DE (2) DE10349979B4 (cg-RX-API-DMAC7.html)
ES (1) ES2319997T3 (cg-RX-API-DMAC7.html)
IL (1) IL174525A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004081A (cg-RX-API-DMAC7.html)
WO (1) WO2005041919A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
CN102481305B (zh) 2009-08-25 2015-08-19 美德阿利克斯株式会社 磷脂酰胆碱的经皮组合物及其制备方法
DE102010028365A1 (de) * 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
BR112014029188B1 (pt) * 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
BR112016030341A8 (pt) * 2014-06-27 2021-07-20 Medytox Inc formulação para a remoção não cirúrgica de um depósito de gordura localizada em um indivíduo, método para a remoção não cirúrgica de depósitos de gordura localizada em um indivíduo que tem acúmulo de gordura localizada, e kit
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US12616651B2 (en) 2014-11-21 2026-05-05 Lipodissolve Therapeutics Inc. Topical lipolysis composition and methods
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3479827B1 (en) 2017-04-21 2023-05-10 AMI Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019150594A1 (ja) 2018-01-31 2019-08-08 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
WO2019203543A1 (ko) * 2018-04-18 2019-10-24 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
KR102939043B1 (ko) 2020-06-01 2026-03-16 코스메드 파마소티컬 씨오 쩜 엘티디 미용용 마이크로니들 어레이
CN116889548B (zh) * 2022-03-31 2026-07-21 四川汇宇制药股份有限公司 一种脂质体递药系统及其制备方法和用途
KR20260079596A (ko) 2023-09-27 2026-06-02 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 리포좀 약물 전달 시스템 및 이의 제조 방법, 리포좀 제제, 용도, 이를 포함한 체지방 감소 약물 또는 의료 미용 제품

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321772A (ja) 1993-03-15 1994-11-22 Rhone Poulenc Rorer Gmbh 水性リポソーム系およびそのリポソーム系の調製法
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
CN1512889A (zh) * 2001-06-05 2004-07-14 用于治疗局部肥胖和脂肪团的药物和/或化妆品组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592C2 (de) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
DE4122744C2 (de) * 1990-08-06 1994-02-03 Nattermann A & Cie Wäßriges Liposomensystem und Verfahren zu seiner Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
JPH06321772A (ja) 1993-03-15 1994-11-22 Rhone Poulenc Rorer Gmbh 水性リポソーム系およびそのリポソーム系の調製法
CN1512889A (zh) * 2001-06-05 2004-07-14 用于治疗局部肥胖和脂肪团的药物和/或化妆品组合物

Also Published As

Publication number Publication date
KR20060117914A (ko) 2006-11-17
HK1096857A1 (zh) 2007-06-15
CN1870977A (zh) 2006-11-29
ATE418965T1 (de) 2009-01-15
WO2005041919A3 (de) 2005-06-23
DE502004008793D1 (cg-RX-API-DMAC7.html) 2009-02-12
EP1684722B1 (de) 2008-12-31
JP2007509085A (ja) 2007-04-12
EP1684722A2 (de) 2006-08-02
DE10349979B4 (de) 2006-05-18
BRPI0415756A (pt) 2006-12-19
WO2005041919A2 (de) 2005-05-12
ES2319997T3 (es) 2009-05-18
CA2543187A1 (en) 2005-05-12
IL174525A0 (en) 2006-08-01
MXPA06004081A (es) 2006-06-27
DE10349979A1 (de) 2005-06-16
AU2004285264A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
US20120329765A1 (en) Medicinal targeted local lipolysis
US20100004216A1 (en) Medicinal lipolysis of accumulation of fat
CN1870977A (zh) 药物靶向的局部脂解
Fraser et al. Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat
JP5826742B2 (ja) 神経損傷及び神経疾患の予防または治療用薬学組成物
KR20060121238A (ko) 축적된 지방의 의약적 지방 분해
JP7415236B2 (ja) エダラボンの経口又は胃内投与を含む処置
CN106535902A (zh) 用于刺激肠内分泌系统以治疗与其相关的疾病或状况的方法和组合物
EP2563370A1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
US20050287199A1 (en) Therapeutic micro nutrient composition for lipolysis and drug delivery
BRPI1007812B1 (pt) Lipoatrofia cosmetic medicinal
US11623000B2 (en) Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same
US20140113883A1 (en) Therapeutic micro nutrient composition for lipolysis and sclerosis
TW202440106A (zh) 用於治療勃起障礙之化合物
US20090221528A1 (en) Therapeutic micro nutrient composition for lipolysis and sclerosis
HK1096857B (en) Medicamentously targeted local lipolysis
US20250222014A1 (en) Composition for localized fat reduction without pain, edema and side effects and method of administration thereof
US8975298B2 (en) Therapeutic agent for pain
US20140274985A1 (en) Systemic administration of androgen in treating dry eye syndrome
HK1096035A (en) Medical lipolysis of fat accumulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096857

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: MAUTZ MEDICINE CO., LTD.

Free format text: FORMER OWNER: AVENTIS PHARMA GMBH

Effective date: 20081031

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20081031

Address after: Frankfurt, Germany

Applicant after: Mautz Pharmaceutical Co Ltd

Address before: Frankfurt, Germany

Applicant before: Sanofi-Aventis Deutschland GmbH

ASS Succession or assignment of patent right

Owner name: MOCI PHARMACY COMBINING CO.,LTD.

Free format text: FORMER OWNER: MAUTZ MEDICINE CO., LTD.

Effective date: 20081121

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20081121

Address after: Frankfurt, Germany

Applicant after: Merz Pharma GmbH & Co., KGaA

Address before: Frankfurt, Germany

Applicant before: Mautz Pharmaceutical Co Ltd

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1096857

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090429

Termination date: 20101009